Navigation Links
HRT Can Lead to Abnormal Mammograms, Biopsies
Date:2/25/2008

That may limit effectiveness of these breast cancer detection methods, study says

MONDAY, Feb. 25 (HealthDay News) -- Women who take combined hormone therapy for about five years have a higher risk of abnormal mammograms and breast biopsies.

This, in turn, may decrease the effectiveness of these methods of detecting breast cancer, according to a new study published in the Feb. 25 issue of Archives of Internal Medicine.

"Women need to be aware of the risks, and it's not just risk of increased breast cancer. It's a risk of possibly having abnormal mammograms and really being tortured by them," said Dr. Kristin Byrne, chief of breast imaging at Lenox Hill Hospital in New York City, who was not involved with the study. "It's a whole slew of things they need to be aware of before making a decision to go on hormone therapy."

Study lead author Dr. Rowan Chlebowski, a medical oncologist with the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, said that for women with severe menopausal symptoms, the new findings "won't be an issue."

"It [hormone-replacement therapy] is safer than we thought maybe a year and a half ago," he said. "Certainly, no one is going to brush off a breast biopsy. But for women trying to decide whether to start on hormone therapy or who want to see if their symptoms get better, they have to think about whether they would mind having a call back" for a mammogram.

The landmark Women's Health Initiative (WHI) study found that combined estrogen plus progestin hormone replacement therapy (HRT) increased the risk of breast cancer. One recent study indicated that the risk was greater for lobular breast cancer than ductal carcinoma malignancy.

Since 2003, there has been a decline in breast cancer incidence that coincided with a decline in HRT use for menopausal symptoms. Nevertheless, Chlebowski pointed out, "a lot of people are still using hormone therapy."

For the new study, the authors looked at 16,608 women who participated in the WHI from 1993 to 1998. The women were randomly assigned to receive combined hormone replacement therapy (estrogen plus progesterone) or a placebo.

Mammograms and breast exams were conducted annually and biopsies performed, if indicated.

More than one in 10 women had otherwise avoidable mammogram abnormalities (an increase of 11 percent), while one out of 25 women had otherwise avoidable breast biopsies (an increase of 4 percent), after taking the hormone therapy for five years.

Ten percent of women in the HRT group had to have a biopsy, compared to 6.1 percent in the placebo group. Yet the biopsies only detected 14.8 percent of cancers in the HRT group, compared with 19.6 percent in the placebo group.

"Your breasts become denser [with HRT], and we all know that mammography isn't as sensitive for the detection of breast cancer in women with dense breasts," Byrne explained.

The increase in abnormal mammograms persisted for at least 12 months even after discontinuing hormone therapy, the study found.

For the medical community, Chlebowski said, this finding "focuses attention that diagnosis is hindered. We have additional imaging modalities, and maybe we should evaluate them to see if we can get rid of this hindrance or delay in diagnosis. It hasn't been a factor for attention before, but it probably should be."

Chlebowski has consulted for several pharmaceutical companies.

A prepared statement from Wyeth Pharmaceuticals, which makes the hormonal product Prempro, said: "While the [study] authors report a link between an increase in abnormal mammograms and breast density among women taking combined estrogen plus progestin, this does not mean they are at an increased risk for breast cancer.

"The data used in this sub-analysis were taken from the combined estrogen plus progestin database of the WHI study and does not reflect the experience of the majority of women taking hormone therapy -- those who take estrogen-alone," the statement concluded.

More information

For more on the Women's Health Initiative, visit the U.S. National Heart, Lung, and Blood Institute.



SOURCES: Rowan T. Chlebowski, M.D., Ph.D., medical oncologist, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center; Kristin Byrne, M.D., chief of breast imaging, Lenox Hill Hospital, New York City; Wyeth statement; Feb. 25, 2008, Archives of Internal Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Siblings of schizophrenia patients display subtle shape abnormalities in brain
2. Chromosome Abnormalities Raise Risk for Autism
3. Body Abnormalities, Childhood Cancer May Share Genes
4. Scientists identify brain abnormalities underlying key element of borderline personality disorder
5. CT colonography detects wide-range of extracolonic abnormalities in elderly patients
6. Abnormal glutamine repeats interfere with key transcription factor, leading to neurodegeneration
7. Abnormal immune cells may cause unprovoked anaphylaxis
8. Grant Supports Study of Abnormal Ring-Shaped Chromosomes
9. Clinical depression linked to abnormal emotional brain circuits
10. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
11. VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP ... today that Karen Pilley has been promoted to Chief Executive Officer. , ... healthcare paradigm – a shift that demands the transition from pay-for-service to pay-for-performance ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for more ... Program (HRRP), the return of a patient to the hospital within 30 days of ... providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has saved ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati ... years of research, development and clinical trials, the founder of Chigurupati Technologies has ... compound of FDA approved ingredients that when infused into alcohol, protect the consumer’s ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection of ... care, NWH has achieved Magnet® recognition for the second time, announced ... The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet rigorous ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... DUBLIN , Feb. 17, 2017 ... ("Theravance Biopharma" or the "Company") today announced the ... novel, potent, and orally administered pan-Janus kinase (JAK) ... 12 th Congress of the European Crohn,s ... the Company reported further data from its completed ...
(Date:2/17/2017)... Research and Markets has announced the addition of the "Drug-Eluting ... ... for the US, Canada , Japan ... Latin America , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... LOUIS , Feb. 17, 2017   FormFast ... has announced a new partnership with Engage , ... the United States . FormFast will serve as ... of Engage,s implementations with MEDITECH .  ... provides essential functionality to complement and enhance the electronic ...
Breaking Medicine Technology: